496 related articles for article (PubMed ID: 32198625)
1. Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing.
Han HA; Pang JKS; Soh BS
J Mol Med (Berl); 2020 May; 98(5):615-632. PubMed ID: 32198625
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Cas9 in genome editing: Its function and medical applications.
Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
[TBL] [Abstract][Full Text] [Related]
3. Potential pitfalls of CRISPR/Cas9-mediated genome editing.
Peng R; Lin G; Li J
FEBS J; 2016 Apr; 283(7):1218-31. PubMed ID: 26535798
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
Vermersch E; Jouve C; Hulot JS
Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
6. Cas9 Cuts and Consequences; Detecting, Predicting, and Mitigating CRISPR/Cas9 On- and Off-Target Damage: Techniques for Detecting, Predicting, and Mitigating the On- and off-target Effects of Cas9 Editing.
Newman A; Starrs L; Burgio G
Bioessays; 2020 Sep; 42(9):e2000047. PubMed ID: 32643177
[TBL] [Abstract][Full Text] [Related]
7. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
8. Design of a generic CRISPR-Cas9 approach using the same sgRNA to perform gene editing at distinct loci.
Najah S; Saulnier C; Pernodet JL; Bury-Moné S
BMC Biotechnol; 2019 Mar; 19(1):18. PubMed ID: 30894153
[TBL] [Abstract][Full Text] [Related]
9. [Mechanisms of the Specificity of the CRISPR/Cas9 System in Genome Editing].
Kulishova LM; Vokhtantsev IP; Kim DV; Zharkov DO
Mol Biol (Mosk); 2023; 57(2):269-284. PubMed ID: 37000655
[TBL] [Abstract][Full Text] [Related]
10. Modulating Cas9 activity for precision gene editing.
Uslu M; Siyah P; Harvey AJ; Kocabaş F
Prog Mol Biol Transl Sci; 2021; 181():89-127. PubMed ID: 34127203
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
12. WheatCRISPR: a web-based guide RNA design tool for CRISPR/Cas9-mediated genome editing in wheat.
Cram D; Kulkarni M; Buchwaldt M; Rajagopalan N; Bhowmik P; Rozwadowski K; Parkin IAP; Sharpe AG; Kagale S
BMC Plant Biol; 2019 Nov; 19(1):474. PubMed ID: 31694550
[TBL] [Abstract][Full Text] [Related]
13. Precision genome editing in the CRISPR era.
Salsman J; Dellaire G
Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 Technology in Translational Biomedicine.
Leonova EI; Gainetdinov RR
Cell Physiol Biochem; 2020 Apr; 54(3):354-370. PubMed ID: 32298553
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
16. Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins.
Lee J; Mou H; Ibraheim R; Liang SQ; Liu P; Xue W; Sontheimer EJ
RNA; 2019 Nov; 25(11):1421-1431. PubMed ID: 31439808
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
18. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
[TBL] [Abstract][Full Text] [Related]
19. Advances in precise regulation of CRISPR/Cas9 gene editing technology.
Cao JX; Wang YL; Wang ZX
Yi Chuan; 2020 Dec; 42(12):1168-1177. PubMed ID: 33509781
[TBL] [Abstract][Full Text] [Related]
20. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
